Cargando…
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
B cell lymphoma therapy has been transformed by CD19-targeting cellular therapeutics that induce high clinical response rates and impressive remissions in relapsed and refractory patients. However, approximately half of all patients who respond to CD19-directed cell therapy relapse, the majority wit...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387338/ https://www.ncbi.nlm.nih.gov/pubmed/35990518 http://dx.doi.org/10.1080/2162402X.2022.2111904 |